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Twenty cases of Epstein-Barr virus (EBV)-associated 
lymphoproliferative syndrome (LPS), defined by the 
presence of EBV nuclear antigen and/or EBV DNA in 
tissues, were diagnosed in 1467 transplant recipients in 
Pittsburgh from 1981-1985. The frequency of occur-
rence in pediatric transplant recipients was 4% (10/ 
253), while in adults it was 0.8% (10/1214) (P < .0005). 
The frequency of LPS in adults declined after 1983 
coincidental with the introduction of cyclosporine mon-
itoring. However there was no apparent decline of LPS 
in children. We describe these ten pediatric cases and 
one additional case of LPS in a child who received her 
transplant before 1981. 
The frequency of EBV infection in 92 pediatric liver 
recipients was 63%. Of these subjects, 49% were sero-
negative and 77% of those acquired primary infection. 
Of 11 cases of pediatric EBV-associated LPS, 10 were 
in children who had primary infection shortly before or 
after transplantation. These results reinforce the impor-
tance of primary EBV infection in producing LPS, 
which was previously shown in adults. Children are at 
greater risk because they are more likely to be seroneg-
ative for EBV and to acquire primary infection. 
Three clinical types of LPS were recognized in chil-
dren. The first (5 cases) was a self-limited mononucleo-
sislike syndrome. The second syndrome (4 cases) began 
similarly, but then progressed over the next two months 
to widespread lymphoproliferation in internal organs 
and death. The third type (2 cases) was an extranodal 
intestinal monoclonal B cell lymphoma, occurring late 
after primary infection. 
Previously we have studied Epstein-Barr virus (EBV) * infec-
tion and EBV -associated lymphoproliferative syndromes (LPS) 
in adults who had undergone kidney, liver, heart, or heart-lung 
transplantations in Pittsburgh (1, 2). Patients who underwent 
primary EBV infections after transplantation were at greater 
risk of developing this complication (2). However the absolute 
number of adults who developed primary infection was low 
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because only 8% of our adult patients were seronegative before 
transplantation and at risk for such infection (3). It was ap-
parent that the situation might be quite different in children, 
who are more likely to be seronegative for EBV. 
In this article we compare the frequency of LPS in adults 
and children who received transplants at the University of 
Pittsburgh Health Center between 1981 and 1985. Then we 
present data on the incidence of primary and reactivation EBV 
infections in the pediatric transplant population, as well as the 
association of these types of infection with clinicallymphopro-
!iferative disease, and we describe the heterogeneous clinical 
features of this entity. 
MATERIALS AND METHODS 
Patient population. From 1981 to 1985, 1214 adults and 253 children 
received organ transplants in Pittsburgh. In adults, there were 725 
kidney, 284 liver, and 205 heart and heart-lung transplantations. In 
children, there were 45 kidney, 193 liver, and 15 heart and heart-lung 
transplantations. To determine the frequency of EBV infection in 
children, 164 liver recipients were studied serologically. 
Diagnosis of EBV infection. Serum specimens were routinely col-
lected on all transplant patients for serologic diagnosis. One specimen 
was collected before or at time of transplant 80 that the pretransplant 
serologic status could be determined. Samples were collected twice 
monthly for the first three months and then once at 6 months and once 
again at 12 months after transplantation. 
Patients _re diagnosed as having a primary EBV infection on the 
basis of de novo development of IgG antibodies against viral capsid 
antigen (VCA). In the absence of documentation of conversion of the 
rgG anti-VCA titer, other serologic changes were taken into account to 
diagnose primary infections. The following are some that helped make 
such a diagn08is: The preaence of IgM anti-VCA titer, the absence of 
anti-Epstein-Barr nuclear antigen (EBNA), and the presence of a 
heterophil agglutination titer (4). Reactivation infection occurring after 
transplantation was based on a fourfold or greater rise in IgG antibody 
titer against VCA in a patient who was seropositive before transplan-
tation. Tests for rgM antibodies against yeA. IgG antibodies against 
early antigen (EA), IgG antibodies against EBNA, and heterophil 
antibodies were determined as previously described (2). 
EBNA and EBV-DNA in tissues. EBV·associated LPS was defined 
by the detection of EBNA or EBV-DNA in tissue. The presence of 
EBNA was determined by anticomplement immunofluorescence (2) on 
cryostat tissue sectiona or cell smears fIXed in acetone. DNA hybridi-
zation tests by Southern blot analysis _re performed in the laboratory 
of one of us (G. Miller) at Yale University. Tissue samples obtained at 
biopsy or autopsy were shipped frozen to New Haven, where the total 
cellular DNA was extracted by the method of Wahl (5). Then 10 I'lJ of 
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cellular DNA, as estimated by optical density, was digested with 40 
units of Bam HI for 3 hr at 37°C and electrophoresed in a 0.8% agarose 
gel. The DNA was transferred by Southern met~~K The blot was 
probed with a chimeric plasmid pACYCl84 contairun~ the EcoRI. B 
fragment of EBV strain FF41 (6). The probe was radiolabelled With 
P32 by nick translation. 
Pathology of bwpsy and autopsy specimens. Snap-frozen tissues were 
stained using the avidin-biotin complex (ABC) technique and commer-
cially available monoclonal antibodies to immunoglobulins, and T cell, 
B cell, and monocyte lineages. Histological tissues were fixed in neutral-
buffered formalin, poetfixed in alcohol-zinc-formalin, and stained with 
the routine diagnostic and immunochemical stains when appropriate. 
Positive and negative controls were included in each batch. 
Statistics. Observed proportions were compared by using the chi-
square test. 
RESULTS 
Freqtumcy of EB V infection after transplantation. Previously 
we reported on the prevalence of antibody to EBV in 134 adult 
kidney, liver, heart, and heart-lung transplant recipients (3). 
To summarize, 92% of transplant recipients were seropositive 
before transplant and 8% were seronegative. After transplan-
tation, the infection rate among the seropositive recipients 
(reactivation infection) was 33%, and the infection rate among 
seronegative recipients (primary infection) was 82% (3). The 
frequency of primary and reactivated EBV infection in pediatric 
transplant recipients from 1983 to 1986 is shown in Table 1. 
Of 164 patients who received transplants during this period, 
pretransplant serologic status was determined for 148; no pre-
transplant sera were available for 16. A group of 92 liver 
recipients had serologic and virologic follow-up for greater than 
60 days and could be evaluated for EBV infection. The mean 
onset of primary and reactivation infection in pediatric liver 
recipients is about 60 days after transplantation (7). Sera 
collected within the f1l'8t 30 days were frequently difficult to 
evaluate because of passive transfer of antibodies from blood 
or blood products transfused at or shortly after the operation. 
It is apparent from Table 1 that 63% of the evaluable patients 
became infected This frequency is significantly higher than in 
adults because there were more children who had primary 
infection (P<0.05). The frequency of primary infection in sero-
negative patients was 77%. The frequency of reactivation in-
fection of seropositive recipients was 48%. These rates are 
similar to those found in the initial study of the first 51 pediatric 
recipients seen in this center in 1983-1984 (7). 
Frequency of lymplwproliferative syndrome (LPS). From 1981 
to 1985, 30 cases of transplant-associated lymphoproliferative 
syndrome were diagnosed in Pittsburgh on the basis of histo-
logic criteria. Of these, 18 cases were in adults and 12 cases 
were in children ::s16 years of age. Ten cases have been excluded 
from this study because their tissues were negative for EBNA 
or EBV-DNA (3 adult patients) or because appropriate tissue 
was not submitted for viral studies (5 adults, 2 children). This 
TABLE 1. Frequency of primary and reactivation EBV infection in 
pediatric liver transplant patients 
Pretransplant No. No. % 
serologic Total 
evaluated infected Infected 
status 
Seronegative 73 (49%) 48 37 77% 
Seropositive 75 (51%) 44 21 48% 
Total 148 (100%) 92 58 63% 
includes 3 from our own previous report (2). It is noteworthy 
that only 3 of 23 tissue samples submitted for viral studies were 
actually negative. However since a clear definition of LPS is 
lacking in the absence of virologic data, it is methodologically 
more rigorous to analyze only cases in which tissues show 
evidence of EBV infection. Thus, our present analysis concerns 
20 patients (10 adults and 10 children) whose tissues had EBNA 
and/or EBV-DNA by nucleic acid hybridization. It should be 
noted that submission of tissue for EBV examination was based 
on clinical indication and not serologic evidence of infection. 
The virological and clinical data of the 10 adults have been 
previously reported and will not be reviewed here (1,2). One 
child (L.S.) was previously described (1, 2), and is also included 
in this study. Another pediatric recipient (K.E.) who received 
a liver transplant in 1972 is not included in the epidemiologic 
assessment (Table 2) but is included in the assessment of 
clinical, laboratory, and pathological data (Table 3). 
Table 2 shows the frequency of EBV -associated LPS in 1467 
transplant recipients from 1981 to 1985. When comparing the 
frequencies of LPS in adults in 1981-1983 and 1984-1985, 
there was a significant decrease from 1.5% to 0.3%. The reason 
for this is unknown, but it may be related to the better control 
of immunosuppression after the practice of administering cy-
closporine by monitoring blood levels was introduced in 1983. 
A comparable decrease was not seen in children. The total 
number of LPS cases was significantly higher in children (4.0%) 
than adults (0.8%) (P<.OOO5). A preponderance of all cases 141 
20, 70%) was associated with serologic evidence of primary 
EBV infection. The remainder, with one exception, had sero-
logic evidence of reactivation (2). 
In order to estimate the risk of developing LPS after either 
primary or reactivation infection, Table 4 was compiled The 
proportion of adult recipients who were seronegative or sero-
positive for EBV and became infected was obtained from the 
study of 134 adult patients cited above (3) and applied to the 
total adult population of 1981-1985. Similarly, the two respec-
tive proportions for children were obtained from Table 1. The 
probability or risk of a seronegative or seropositive patient, as 
well as one with acquired primary or reactivation infection, 
developing LPS is illustrated in the last column. For example, 
8% of 124 seronegative children, and 10.5% of children with 
TABLE 2. Incidence of EBV -associated lymphoproliferative syndrome 
in adults and children who received transplants in Pittsburgh 
Type of patient 1981 1982 1983 1984 1985 Total 
Adults 
Children 
Both 
PrimaryEBV 
Infection 
1/127" 4/171 3/228 
0.8% 2.3% 1.3% 
8/526 (1.5%)" 
0/17 2/35 0/42 
0% 5.7% 0% 
2/94 (2.1%) 
1/144 6/206 3/270 
0.7% 2.9% 1.1% 
1/1d 2/6 2/3 
100% 33% 67% 
2/324 0/364 
0.6% o % 
2/688 (0.3%)" 
4/74 4/85 
5.4% 4.7% 
8/159 (5.0%) 
6/398 4/449 
1.5% 0.9% 
5/6 4/4 
83% 100% 
" No. recipients with LPS/total No. recipients. 
b P<0.OOO5. 
• P<0.05. 
1O/1214b 
0.8% 
1O/253b 
4.0% 
20/1467 
1.4% 
14/20 
70% 
d No. recipients with LPS and primary EBV infection/No. recipients 
with LPS. 
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TABLE 3. Clinical, laboratory, and pathology findings of EBV-UIIOCiated lymphoproliferative syndrome" 
Laboratory Findings Tissue evidence of Age Clinical EBV 
at fmdings Pathological PatientSu tx Months VCA and findings Outcome EBV DNA (yean) Event post- EBNA HA/MS Isolation treatment EBNA hybridization 
transplant IgG IgM 
KH F 2.2 EBV info Pre-Tx 5 20 <5 ND ND Fever, abdominal pain. Tonsils, lymph node: Inguinal Tonsil (+) Recovered 
tonsillitis, polymorphous node 
WBC=3300, nonmalignant pro- (+) 
ATL=10% liferation 
Hz: acyclovir and re-
duced cyclosporine 
Clin.on- 2 10 10 10 + 
j' set !;<. 
f CC M 7.9 Pre-Ts <5 <5 <5 NO NO Fever, lymphacienop- Tonsils, inguinal Tonsil Tonsil (+) Recovered athy, splenomegaly, node: polymor- (-) possible 
EBV info 1.5 10 5 <5 NO + tonsillitis, phous nonmalig- chronic 
WBC=3000, nant proliferation infec-
ATL=30% tion 
Clin.on- 7 1280 10 <5 Rs: acyclovir and re-
set duced cyciosporine, 
2 years later, epi-
sodes of fever and 
adenopathy 
KL M 3.1 Pre-Tx <5 <5 <5 ND ND Fever, abdominal pain, Cervical lymph node: Cervical Cervical Recovered 
cervical\ymphade- polymorphous node node (+) 
EBV 11 320 5 5 nopathy, nonmalignant pro- (+) 
inf./ WBC=6700, liferation 
clin. ATL=3% 
onset Rx: reduced cyclospor-
ine 
DW M 14.6 Pre-Ts <5 10 <5 ND NO Fever, sore throat, Tonsils: polymor- Tonsil ND Recovered 
tonsillar enlarge- phous nonmalig- (+) 
EBV 6 80 <5 5 ND ment, cervical ade- nant proliferation 
inf./ nopathy 
clin. Rx: reduced cyciospor-
onset ine and prednisone 
RO M 1.2 Pre-Tx NA NA NA NO NO Purulent rhinorrhea, N 880pharyngeal Nose ND Recovered 
difficulty breathing, mass: focal infU- mass 
EBV 11 160 <5 <5 NO + recurrent otitis me- tration of plasma (+) 
inf./ dia, WBC=2900, cells (nonmalig-
clin. ATL=rare nant) 
onset Rx: reduced cyclospor-
ine and prednisone, 
Imuran discontinued 
JC M 5.8 Pre-Tx <5 <5 <5 NO NO Fever, diarrhea, jaun- Kidney,liver, mar- Mes- Mesenteric Died 2 
dice, enlarged ton- row, lymphoid sys- en- node (+) months 
EBV 2 20 5 <5 sils and spleen. liver tem: diffuse lym- teric post-
inf./ bx-immunoblasts, phoproliferative node trans-
clin. G! and cerebral process; monomor- (+) plant 
onset hemorrhages from phous larp cell 
coagulopathy, lymphoma, B cells 
WBC=14,500, by immunoperoxi-
ATL=80% due 
Hz: cyclosporine and 
steroids reduced 
KE F 1.7 Pre-Ts <5 <5 <5 ND NO Fever, sore throat, Tonsils: polyclonal Tonsil Tonsil (+) Died 3 
jaundice, tonsillar polymorphous (+) weeks 
EBV 154 <5 <5 <5 + NO and cervical node lymphoid hyper- after 
inf./ enlargement plaaia; at autopsy, onset of 
clin. ATL=55% polymorphous in- syndrome 
onset fUtrates of liver, 
kidneys, lungs, in-
testinal wall, 
brain, etc_ 
'I I ..•.. 
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TABLE 3. Clinical, laboratory, and pathology tindinga of EBV -888OCiated lymphoproliferative syndrome" 
Laboratory Findings Tissue evidence of Age Clinical EBV 
at findings Pathological Patient Sex Monthe VCA and findings Outcome tx EBV DNA (years) Event poet- EBNA HA/MS Isolation treatment EBNA hybridization transplant IgG igM 
MM F 8.6 Pre-Tx NA NA NA NO NO Typical "mono;" 5 Tonsils: polymor- Mes- Mesenteric Died 1 
months later, tonsil- phous polyclonal en- node (+) month 
EBVinf. 20 1280 40 <2 NO NO litis with polyclonal lymphoid hyper- teric after 
hyperplasia and re- plasia; at autopsy node onset of 
Clin.on- 25-37 320 80 <5 NO mission. 12 months diffuse monomor- (-) second 
set later, anemia, oil- phous infUtrates syn-
lary adenitis, acute in liver, pericar- drome 
renal failure, hypo- dium, and most 
gammaglobulinemia, organs; large cell 
respiratory distress. lymphoma 
Rx: acyclovir, cessa-
tion of cyclosporine. 
CB F 11.8 Pre-Tx 20 5 <5 NO NO Fever, deterioration of Liver bx: polymor- Liver Liver (-) Died 2 
liver function, coag- phous lymphopro- (+) months 
EBV 1 20 40 5 ND ulopathy and intra- liferation; lung bx: post-
inf./ cerebral hemor- CMV pneumonia; trans-
clin. rhage, WBC=600, autopsy: lympho- plant 
onset ATL=10% proliferative syn-
drome involved 
lymph nodes, GI 
tract, liver 
JM M 4.2 Pre-Tx <5 <5 <5 NO NO Exudative pharyngitis, Perforated ileal tu- Ileal tu- Ileal tumor Relapses 
WBC=8100, mor; monomor- mor (+) 
EBV info 1 10 5 <5 NO + ATL=occ,23 phous monoclonal (+) 
months later, rectal IgM lambda lym-
Clin.on- 24 640 20 <5 NO NO bleeding, abdominal phoma 
set pain and tenderness, 
suspected appendici-
tis. Laparotomy re-
vealed ileal and 
mesenteric masses. 
Readmitted twice 
for resection of re-
current tumors 
Rx: excision of masses; 
cyclosporine reduced 
LS M 16.5 Pre-Tx <5 NO ND ND NO Fever, diarrhea, perito- Intestinal tumor: Intes- Intestinal Recovered 
nitis, laparotomy re- large cell immu- tinal tumor 
EBV 3 20 <5 <5 NO vealed multiple tu- noblastic lym- tumor (+) 
inf./ mors and perfora- phoma, monoclo- (-) 
clin. tion. WBC=3800 nallambda, IgG 
onset Rx: excision of tumor; predominant 
acyclovir; with-
drawal of immuno-
suppression (allo-
graft lost) 
a Abbreviations used: NA: not available; NO: not done; EBV: EBV infection, as defined by first serologic evidence; WBC = white blood cells; 
A TL = atypical lymphocytes; HA/MS: heterophil antibodies, monospot test. 
primary EBV infection may develop LPS. It is clear that the 
probability that LPS will occur in a seronegative patient or a 
patient who undergoes primary infection is higher in both 
adults and children. The difference is significant for both adults 
(P<O.OO5) and children (P<O.OO5). 
The Spectrum of LPS in children. Table 3 summarizes the 
clinical, laboratory, and pathological data of 11 pediatric cases 
of EBV -associated LPS. Figure 1 shows the EBV nucleic acid 
hybridization by Southern blot. 
One of the difficulties in diagnosing EBV infections in these 
patients is that often the "pretransplant" serum was obtained 
during the operation and the sample was often contaminated 
by transfused blood (7). 
Of the eleven patients, 7 were clearly seronegative before 
transplantation. Six of these converted their anti-VeA titer 
after transplantation and clearly underwent primary infection. 
One patient (K.E.), whose pretranspIant serum was negative 
for anti-yeA, died three weeks after transplantation, before 
her EBV serology titers could convert. Evidence that she had 
primary infection was the presence of a positive heterophil 
~~~ .. --~-------
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TABLE 4. Eatimated risk of developm, EBV -aaaociated 
lymphoproliferative ayndrome after EBV infection after 
tranaplantation 
Estimated riak 
Patient 
type 
EBV I N % No. No. with--------
sero OIlY o. Infected Infected LPS No. LPS/ No. LPS/ 
Pre-Tx patient group No. infected 
Adulta Negative 100 82% 82 4 4.0% 4_9% 
Adulta Positive 1114 33% 368 6 0.5% 1.6% 
Children Negative 124 77% 95 10 8.0% 10.5% 
Children Positive 129 48% 62 0 0% 0% 
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FIGURE 1. Southern blot showing the preaence of EBV DNA in 
tisaue samples from 7 children with lymphoproliferative syndromea 
follOwing liver transplantation. Cellular DNA was digested with Bam 
HI and probed with the EcoRI B fragment of EBV DNA cloned in 
pACYCl84. The Bam HI subfragmenta found in EcoRI B are shown 
at the left and right margins. The terminal Bam HI fragmenta (Bam 
HI Ef and Bam HI Gf) are different size in the probe (lane 13) since 
they contain EcoRI sites. Tissue samplea from patients in group 1 
(nonfatallymphoproliferative disease) are found in lane 4 (K.H. tonsil), 
lanes 6 and 8 (C.C. tonsil and axillary node), and lane 7 (K.L. cervical 
node). Samples from patients with fatallymphoproliferative disease, 
group 2, are seen in lane 2 (M.M. mesenteric node) lane 5 (J.C. 
mesenteric node), and lane 11 (K.E. tonsil). The sample in lane 9 is 
the gut lymphoma from J.M. The signal in lane 13 with plasmid DNA 
is equivalent to about 18 copies of the EBV genome per cell. 
agglutination (monospot test) and the evidence of EBV infec-
tion in tissues. Our serologic interpretation of the remaining 4 
patients is as follows. 
The "pretransplant" sera from KH. and C.B. were positive, 
probably because the serum samples were obtained at the time 
of operation while the patients were being transfused. However 
both had positive IgM titers and no anti-EBNA, suggesting 
that they were undergoing a primary infection around the time 
of the operation or just before it. KH. also had EBV isolated 
de novo from the mouth. 
A "pretransplant" serum was not available on M.M. However 
the elevated IgO and IgM anti-VCA titers and absence of anti-
EBNA are indicative of a primary infection. 
A "pretransplant" serum was not available for R.O. His only 
available serum posttransplant was positive for anti-VCA, but 
negative for IgM and anti-EBNA. It was not possible to diag-
nose primary EBV infection in this patient. In summary we 
believe that 10 of 11 patients had evidence of primary infection 
around the time of, or after, transplantation. 
The IgM titers converted in 4 patients. They were elevated 
in 4 others but not elevated in 3. IgM antibody to VCA is 
frequently low in our immunosuppressed populations who de-
velop de novo EBV infection and may even be absent (2)-and 
in our opinion it is not as useful in diagnosing primary infection 
as in the immunocompetent (4). The anti-EA titers (not shown 
in Table 3) were positive in 6 patients and negative in 5. We 
have found that these determinations are neither entirely spe-
citic nor sensitive for de novo infection. They are also fre-
quently positive in the absence of other signs of infection (2). 
Notably, antibody against EBNA failed to develop in 7 of 11 
patients, and titers of only 1:5 developed in 3. The absence of 
an anti-EBNA response, or a low response, is also characteristic 
of immunosuppressed patients, and is quite useful in the diag-
nosis of primary EBV infection in this group of patients (2,8). 
Only 1 of 6 patients tested developed heterophil antibodies 
as determined by monospot tests. While it is well known that 
such antibodies may not develop in children undergoing pri-
mary EBV infection (9), this too may be an expression of 
immunosuppression, as adult transplant recipients undergoing 
primary infection also rarely developed heterophil antibodies 
(2). 
Nine of the 11 patients developed serologic evidence of EBV 
infection shortly before or in the first year after transplanta-
tion, mostly within the first 6 months. One patient became 
infected at 2 years (J.M.) and one (KE.) at 12.8 years after 
transplantation. In 9 cases clinical symptoms attributable to 
EBV infection occurred around the time of infection. However 
in C.C., they occurred 6 months later; and in J.M., 2 years later. 
In the latter case, a well defmed intestinal lymphoma wss 
involved. 
Clinically, these 11 cases present 3 distinguishable syn-
dromes. These are a self-limited form of mononucleosis syn-
drome with localized LPS, a similar syndrome progressing to 
widespread lymphoproliferation and death, and isolated extra-
nodal lymphoma. 
Four patients (KH., C.C., K.L., and D.W.) had moderately 
severe attacks of EBV mononucleosis. All these patients are 
still living 2-3 years after onset of their illness, although one 
patient (C.C.) had subsequent episodes of fever and lymphade-
nopathy. A fifth patient (R.O.) developed an isolated nssopha-
ryngeal mass associated with the adenoids that had EBNA. 
This was excised without further problems. Case histories of 
two illustrative cases are given here. 
KH. developed a clinical syndrome consistent with EBV 
mononucleosis two months after transplantation (Table 3). She 
underwent a tonsillectomy for airway obstruction and an in-
guinal node biopsy. The tonsillar tissue contained EBV-DNA 
and a right inguinal lymph node biopsy wss positive for EBNA. 
Both tissues showed nonmalignant polymorphous B cell hyper-
plasia. The course of the illness was about one month. The 
patient has remained well except for a subsequent attack of 
varicella from which she recovered. 
C.C. developed primary EBV infection 1.5 months after 
transplantation based on conversion of IgG anti-VCA titer. He 
remained asymptomatic untilRlIK~ months later when he devel-
oped tonsillar and lymph node enlargement after a course of 
treatment for rejection that included OKT3 antiserum. His 
anti-VeA titer rose to 1:5120, and IgM titers remained positive. 
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The tonsil and inguinal node both showed polymorphous non-
malignant lymphoid proliferation. The tonsil was negative for 
EBNA but positive for EBV-DNA (Fig. 1). The patient was 
treated with acyclovir and reduction of cyclosporine. Fever 
resolved and lymph nodes regressed, but 10 months later the 
patient was readmitted for fever and lymphadenopathy. A left 
axillary node showed granulomatous, necrotizing adenitis and 
was positive for EBV-DNA. The patient may have had chronic 
relapsing EBV infection. 
In four other patients (J .C., K.E., M.M., and C.B.), the illness 
began very much like those above but it had a fulminating 
course with fatal outcome. J.C. and M.M. had what appeared 
to be large cell lymphomas, but K.E. and C.B. had diffuse 
polymorphous lymphoproliferation. In the case of C.B., CMV 
pneumonia was also present terminally and may have contrib-
uted to her demise. Two of these cases are described briefly. 
Two months after transplantation, J.C. developed fever, diar-
rhea, jaundice, tonsillitis, splenomegaly, leukocytosis, and a 
striking atypical lymphocytosis (80%) concomitant with sero-
logic evidence of primary EBV infection. His death was due to 
gastrointestinal and cerebral hemorrhages as a result of hepa-
togenic coagulopathy. At postmortem, in addition to a gener-
alized aspergillus infection, there was a widespread lymphom-
atous involvement of the kidneys, liver, gut, bone marrow, and 
lymphoid system. Histologically, this process was a monomor-
phous large cell lymphoma with many mitoses. Plasmacytoid 
features were minimal. Areas of necrosis were prominent. A 
mesenteric lymph node was positive for EBNA and EBV -DNA 
(Fig. 1). 
K.E. developed fever, sore throat, jaundice, and a positive 
monospot test 154 months after transplantation. A right ton-
sillar biopsy revealed the presence of EBNA and EBV-DNA 
(Fig. 1). All immunosuppression was discontinued but this did 
not affect the clinical course. She died of asphyxiation during 
an episode of hematemesis. At autopsy, a diffuse polyclonal 
lymphoproliferation was found that had infiltrated the liver, 
kidneys, pancreas, salivary glands, lungs, adrenal glands, ova-
ries, uterine wall, bone marrow, brain, meninges, and peripheral 
nerves. The mucosa and submucosa of the entire gastrointes-
tinal tract, and the serosa of the large intestine were also 
involved. The lymphoproliferation was pleomorphic, not mon-
omorphous as in J.C., and had pronounced plasmacytoid fea-
tures. By immunoperoxidase staining the cells had B lympho-
cyte masses, with immunoglobulin production, and both light 
chains equally represented 
The third clinical form of LPS is that of an isolated lym-
phoma (J.M., 1.S.) typified by the case described below. One 
has had relapses (J.M.) and one (L.S.) has recovered with 
withdrawal of immunosuppression (Table 3). 
J.M. developed serologic evidence of primary EBV infection 
one month after transplantation but he was asymptomatic. He 
did well until two years later when he had an episode of 
hematochezia. His hematocrit remained stable, and the bleed-
ing was thought to be self-limited Two weeks later, he was 
admitted with abdominal pain, rebound abdominal tenderness, 
and leukocytosis. A laparotomy was performed for suspected 
appendicitis. A perforated ileal mass and a mesenteric mass 
were found and resected A diffuse lymphoproliferative lesion 
consistent with a lymphoma was found infiltrating all layers of 
the small bowel. Ulceration into the gut lumen and large areas 
of necrosis were present. The cells were intermediate in size 
(different from J.C. and M.M., in whom they were large cell or 
immunoblastic) with minor or moderate plasmacytoid features. 
IgM lambda immunoglobulin was readily demonstrable and the 
tumor was monomorphous. EBNA was found in the tumor, and 
EBV-DNA was also present by hybridization studies (Fig. 1). 
Postoperatively immunosuppression was withheld for one 
week, and then cyclosporine was given at one-half the previous 
dosages (50 mg twice daily). Prednisone was maintained at 5 
mg daily. The patient has been readmitted twice for progressive 
tumors and a tumor resection was performed 6 months after 
the first resection. Cell markers were identical on this second 
tumor. 
The pathology of lymphoproli{erative syndrome. Two broad 
pathologic patterns were discerned that were similar to what 
Frizzera et al. (10) classified as polymorphous diffuse B cell 
hyperplasias and lymphomas. The flfSt pattern was seen in the 
lymph nodes and tonsils and adenoids of all patients of the 
first group (e.g., Fig. 2); it was also seen in C.B. and in the 
initial tonsillar lesion of K.E. and M.M. in the second group. 
This polymorphous reaction often contained vascular throm-
boses and tissue necrosis. There was usually more necrosis in 
the tonsils than lymph nodes and the cells were a mixture of 
plasma cells, plasmacytoid lymphocytes, and histiocytes of 
varying morphology. 
The second pattern noted was a monomorphous lymphoma-
like proliferation (M.M., Fig. 3). It was seen in some patients 
with the second and in both patients with the third clinical 
pattern (J.C., M.M., J.M., and L.S.). These tumors also con-
tained necrotic areas. However these were not confined to nodes 
but involved internal organs and formed sheets of cells. Tumors 
from J.M. and 1.S. contained monotypic IgM>' by immuno-
globulin analysis; one had B cells but no immunoglobulins 
(J.C.), and the third had only a few cells with B cell markers. 
DISCUSSION 
EBV infects most of the population and causes little signifi-
cant disease. In Pittsburgh, 92% of the adult transplant popu-
lation have serologic evidence of previous infection (3), and 
half the pediatric transplant population is seropositive (7) 
before operation. 
However when EBV infects immunologically compromised 
individuals, an ordinarily innocuous infection may develop into 
any of a number of dangerous diseases. Immunosuppression 
may be congenital or acquired. In one type of poorly understood 
congenital immunodeficiency, an X-linked as well as a non-X-
linked lymphoproliferative syndrome has been described, in 
which the patient is unable to handle EBV mononucleosis, and 
a fatal disease with lymphoproliferations in major organs may 
develop (11, 12). In ataxic telangiectasia, patients have a high 
incidence of lymphoreticular malignancies that may show evi-
dence of EBV-DNA (13). In acquired immune deficiency syn-
drome, B cell lymphomas with evidence of latent EBV infection 
and chromosomal translocation typical of Burkitt's lympho-
mas, as well as other types of non-Hodgkin's lymphomas have 
been described (14, 15). 
The posttransplantation state represents one form of ac-
quired immunodeficiency produced iatrogenically. Under 
azathioprine as well as cyclosporine immunosuppression, spe-
cific immune mechanisms against EBV, particularly cytotoxic 
T cell immunity, appear to be depressed. This is manifested by 
the absence of effective regression of EBV-infected B cells in 
vitro, and increased oral virus shedding by transplant recipients 
(16, 17). As with cytomegalovirus (CMV), there is intense 
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FIGURE 2. Tonsil from K.H. The polymorphous nature of the pro-
liferation is readily apparent. Small lymphocytes, plasma cells, and 
histiocytes 8Ie among the cell types seen. Mitoses are present. 
FIGURE 3. Abdominal lymph node from autopsy of M.M. The mon-
omorphous l8Ige cell population, with prominent nucleoli, most closely 
resembles an immunoblastic sarcoma. In this instance only some B cell 
m8Ikers, but not immunoglohulins, were demonstrable on the cells. 
infective activity by EBV during the immediate posttransplant 
period. The rate of infection with EBV, comprising both pri-
mary and reactivation infection, is about 41 % of all transplant 
recipients (Table 4). 
Even in immunosuppressed subjects, most EBV infections 
are clinically silent. A small but significant proportion of pa-
tients, however, develop apparent disease (18). One life-threat-
ening entity is the spectrum of clinical syndromes that may be 
called EBV-associated lymphoproliferative syndromes (LPS) 
first defined in transplant patients by Hanto et al. (19). We 
recently described the importance of primary EBV infection in 
adult transplant recipients who developed LPS (3). In this 
report, the association is even more strikingly demonstrated in 
children. In 11 cases of EBV -associated LPS in pediatric trans-
plant recipients, 10 had serologic evidence of primary EBV 
infection. It is interesting that while EBV -associated LPS in 
adults appeared to decrease in frequency after 1983, its inci-
dence in children has not changed appreciably despite intro-
duction of monitoring of immunosuppressants by measuring 
blood levels of cyclosporine. The fact that previously uninfected 
recipients are those at greatest risk for the development of LPS 
suggests the need to investigate the source of EBV infection. 
In the case of CMV, the source has been traced in most cases 
to the donor organ or blood products used during the periop-
erative period (20). However so far we have not been able to 
incriminate the donor organ or blood products as source of 
EBV infection (7). 
On the basis of experience at the University of Minnesota, 
Hanto et al. (21) divided. EBV -associated LPS into three cat-
egories. Group 1 represents "polymorphic diffuse B cell hyper-
plasia," without evidence of malignancy. Clinically the illness 
resembles EBV mononucleosis. Group 2 represents "poly-
morphic B cell lymphoma." This illness is also mononucleosis-
like, but tissues may show morphologic features of malignancy. 
There may be a "risk of progression from a polyclonal to a 
monoclonal B cell proliferation" (21) . Group 3 includes "older" 
patients who develop extranodal tumors that are monoclonal 
and malignan t. 
The three syndromes described in our children, correspond 
well clinically and pathologically to Hanto's three groups. Our 
first group consists of mononucleosis syndrome with only be-
nign polymorphous hyperplasia. Our group 2 showed. progres-
sive fatal lymphoproliferation. Pathologically one patient 
showed the same type of benign hyperplasia as in our group 1, 
but the other two showed a malignant transformation similar 
to Hanto's group 2. It is quite possible that groups 1 and 2 
represent a continuum ranging from benign mononucleosis to 
widespread immunoblastic or lymphomatous proliferation in 
vital organs. Our group 3 consists of a 4-year-old boy and a 16-
year-old boy who developed monomorphous gastrointestinal 
lymphomas. Cells cultured from the tumor of the first patient 
have shown a chromosomal translocation (8 to 14) such as is 
found in Burkitt's lymphoma (unpublished data [22]). This 
patient has relapsed twice despite resection of the tumor and 
decrease in immunosuppression. 
The three syndromes we describe are also consistent with 
what has been observed in the X-linked lymphoproliferative 
syndrome. An analysis of 161 patients and 44 kindreds by 
Grierson et al. (23) revealed 3 major patterns: fatal EBV 
mononucleosis, acquired hypogammaglobulinemia, and malig-
nant lymphoma. The fatal mononucleosis syndrome is similar 
to that in our second group. It is interesting that severe hypo-
gammaglobulinemia was seen in one of our patients who had 
' the fatal mononucleosis syndrome (M.M.). The precise immune 
aeficiency in X-linked, as well as non-X-linked, lymphoprolif-
erative syndromes is unclear. In the former a number of B cell 
abnormalities, including low IgA and IgM levels and inability 
to respond to tJ>X 174 antigen by specific IgG production have 
been described (23). A deficient natural killer cell response has 
been suggested in the latter syndrome (12), In the X-linked 
syndrome, an excess rather than a deficient cytotoxicity re-
sponse has also been postulated as the cause of the severe 
hepatitis seen in fatal disease (24). Infiltration in the liver was 
a prominant feature in all 4 of our patients who died, 2 of whom 
had bleeding coagulopathies. These interesting observations 
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suggest that the precise nature of the immune defect accounting 
for the abnormal response to EBV in transplant recipients 
remains to be further defined. 
Our pediatric patients with LPS appear to be different from 
adult patients in many respects. First, EBV -associated LPS 
does not appear to be decreasing as it is in adult recipients 
despite better cyclosporine monitoring (Table 2, [25]). It is 
possible that children are less well able to cope with primary 
EBV infection. We may also be seeing more LPS in children 
because proportionately more have primary infection, and liver 
transplantation in children has increased since 1984. Second, 
the presentation of LPS is different in children. Half the 14 
LPS cases described in adults from Pittsburgh were intestinal 
tumors (1, 2). Only 2 of 11 children had such an extranodal 
presentation. So far we have not seen the late central nervous 
system lymphomas reported from Minnesota and Stanford in 
our adult or pediatric transplant recipients (21, 26). 
The outcome varied in the three clinical groups described. 
Patients of the first group were first seen with a typical mono-
nucleosis syndrome. Involved tissues, which showed a polymor-
phous reactive proliferation, were limited to lymph nodes and 
tonsils. These patients had a benign clinical course. 
The second group had the worst prognosis. Lymphoprolifer-
ation extended to extranodal organs, particularly the liver. 
Even when proliferation remains histologically a polymorphous 
reactive type (K.E.), hemorrhages caused by liver failure (J.e., 
e.B., K.E.) may lead to a fatal outcome. Two patients in this 
group (J.e. and M.M.) showed a monomorphous large cell 
lymphoma that terminally invaded multiple organs. Hanto et 
al. (21) believe that a monoclonal lymphomatous proliferation 
may result,from an initially polymorphous process. Indeed our 
patient M.M. initially had a mononucleosis syndrome with 
polymorphous polyclonal lymphoid hyperplasia in the tonsils 
before she developed monomorphous generalized lymphoproli-
feration that led to her death. We do not yet know, in this case, 
the clonality of the infiltration-and we do not know how one 
syndrome pathogenetically leads to the other. 
The third type represents extranodal lymphomas in which 
the role of EBV is unclear. It is unlikely that the presence of 
EBV genomes or their expression in tumor tissue is adventi-
tious, as they have not been found in the usual non-Hodgkin's 
lymphomas (27). To what extent independent viral replication 
and infection takes place, and to what extent there is just clonal 
expansion of latently infected tumor cells, is also unknown. 
The finding that some posttransplant LPS are oligoclonal by 
immunoglobulin gene rearrangement (28) has not clarified the 
picture. Our two patients (J.M. and L.S.) had isolated extra-
nodal intestinal lymphomas that were monomorphous in ap-
pearance and monoclonal in immunoglobulin synthesis. One 
patient in particular also has an 8-to-14 chromosomal translo-
cation (J.M., unpublished data). Klein postulates that trans-
formation of B cells by EBV alone is inadequate for oncogenesis 
and that, in addition, one or more chromosomal translocations 
that may facilitate oncogene expression are necessary. Weare 
still studying the immunoglobulin clonality of our specimens, 
but more direct experimental studies to test this hypothesis 
would be desirable. 
The appropriate therapy for EBV -associated LPS is at best 
empirical and remains a challenge. Hanto et al. (21, 29) believe 
that acyclovir may be useful, particularly in patients in their 
groups 1 and 2, in whom active EBV replication may play a 
role in the pathopneaia. Acyclovir has been used extensively 
in Pittsburgh. Of the 11 patients described here, 8 received 
acyclovir and also had their immunosuppression decreased; 4 
have recovered without apparent clinical relapse, after a max-
imum of 6 years of follow-up. However no firm conclusions can 
be drawn from such uncontrolled observations, and controlled 
trials are needed. During acyclovir administration, EBV oral 
shedding is suppressed, but it always reappears after the drug 
is stopped (30). Better anti-EBV agents are clearly needed. 
In a previous report, we reported that both monoclonal and 
polyclonal tumors responded to decrease of immunosuppres-
sion. In a number of cases, as pointed out by Hanto et al. (21), 
the tumor was also surgically excised. The case of J.M. shows 
that recurrences may also occur with decrease of immuno-
suppression. Further studies are needed to correlate type of 
LPS-in terms of histology, clonality, immunoglobulin gene 
arrangement, and EBV expression-with response to therapy 
and prognosis. 
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USE OF OKT3 MONOCLONAL ANTIBODY IN THE TREATMENT OF 
ACUTE CARDIAC ALLOGRAFT REJECTION 
JON B. KLEIN/ KENNETH R. McLEISH, C. MARTIN BUNKE, BRUCE CHANG, BRIAN L. GANZEL, 
A. DAVID SLATER, AND LAMAN A. GRAY JR. 
Departments of Medicine and Surgery. School of Medicine, University of Louisville; and the LouisviUe Institute for Heart and Lung 
Disease. Louisville, Kentucky 
OKT3 is a murine monoclonal antibody that recog-
nizes the T3 surface antigen present on mature T cells, 
and it has been used to successfully treat renal allograft 
rejection. We report our experience with OKT3 in the 
treatment of cardiac allograft rejection. Eight patients 
with endomyocardial biopsy evidence of moderate or 
severe rejection were given fourteen daily intravenous 
treatments of OKT3. Six of the eight patients had com-
plete recovery following OKT3 therapy; one required 
additional steroid therapy for recurrence and one pa-
tient failed to respond. Five of the six patients with a 
complete respolUle have experienced no further rejection 
(mean follow-up 437 days). Adverse reactions to OKT3 
1 Addreaa reprint requests to: Jon B. Klein, M.D., Division of Ne-
phrology, School of Medicine, University of Louisville, Louisville, KY 
40292 . 
were common early in the treatment course, but were 
well tolerated. We concluded that OKT3 is a safe and 
effective treatment of cardiac allograft rejection and 
that a majority of patients experience long-term rejec-
tion-free periods. 
The survival of cardiac transplant patients has increased 
significantly in the past five years (1). Contributing factors 
include the introduction of cyclosporine, stringent patient se-
lection criteria, and the early diagnosis of graft rejection by 
endomyocardial biopsy (2, 3). Despite these advances, acute 
rejection of the allograft remains a major source of morbidity 
in the cardiac transplant patient. Conventional therapy has 
relied upon high·dose steroids and antilymphocyte globulins 
(ALG)* (4, 5). High-dose steroids are associated with an in-
* Abbreviation used: ALG, antilymphocyte globulin. 
